Daily Stock Analysis, AUPH, Aurinia Pharmaceuticals Inc, priceseries

Aurinia Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
6.41
Close
6.57
High
6.67
Low
6.39
Previous Close
6.42
Daily Price Gain
0.15
YTD High
7.85
YTD High Date
Jan 16, 2019
YTD Low
6.00
YTD Low Date
Jan 28, 2019
YTD Price Change
-0.27
YTD Gain
-3.95%
52 Week High
7.85
52 Week High Date
Jan 16, 2019
52 Week Low
5.01
52 Week Low Date
Apr 2, 2018
52 Week Price Change
1.28
52 Week Gain
24.20%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 18. 2017
2.38
Feb 22. 2017
3.43
24 Trading Days
44.30%
Link
LONG
Mar 1. 2017
3.71
Mar 24. 2017
8.08
17 Trading Days
117.73%
Link
LONG
May 10. 2017
7.35
May 15. 2017
7.77
3 Trading Days
5.71%
Link
LONG
Jan 2. 2018
4.85
Jan 26. 2018
5.65
17 Trading Days
16.39%
Link
LONG
Dec 26. 2018
6.00
Jan 22. 2019
6.96
17 Trading Days
16.04%
Link
Company Information
Stock Symbol
AUPH
Exchange
NasdaqGM
Company URL
http://www.auriniapharma.com
Company Phone
250-708-4272
CEO
Richard M. Glickman
Headquarters
British Columbia
Business Address
#1203-4464 MARKHAM STREET, VICTORIA BC, CANADA V8Z 7X8
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001600620
About

Aurinia Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovering and developing immunomodulating therapeutics. The company's pipeline includes voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Description

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.